Literature DB >> 12667679

Flow cytometry based detection of HLA alloantibody mediated classical complement activation.

Markus Wahrmann1, Markus Exner, Heinz Regele, Kurt Derfler, Günther F Körmöczi, Karl Lhotta, Gerhard J Zlabinger, Georg A Böhmig.   

Abstract

Complement-dependent cytotoxicity (CDC) panel reactive antibody (PRA) testing is used to assess recipient presensitization and post-transplant alloantibody formation in transplant recipients. However, CDC test results can be affected by false-positive reactions brought about by autoantibodies or antilymphocyte reagents. As an alternative to the CDC-PRA assay, detection of HLA alloantibodies using HLA antigen-coated microbeads (FlowPRA test) was recently established. FlowPRA testing, however, does not distinguish between (presumably more harmful) complement-fixing and noncomplement-fixing alloantibodies. In this study, we established a novel assay allowing flow cytometric detection of HLA alloantibody dependent classical complement activation using the FlowPRA test. For the detection of complement activation, FlowPRA beads were incubated with sera from highly sensitized dialysis patients (CDC-PRA reactivity >60%) and then stained for C4 (C4d, C4c) and C3 (C3d, C3c) fragments, as well as C1q deposition using indirect immunofluorescence. We demonstrate alloantibody induced induction of C4 fragment, and in parallel C1q deposition to HLA class I or class II beads. As shown by immunoblotting, C4 staining was not due to the presence of preformed C4 fragment-IgG/M complexes. Indeed, C4 fragment deposition in our in vitro system was demonstrated to result from de novo complement activation. First, inactivation of C4 by treatment of sera with methylamine, which inhibits cleavage of the internal thioester, completely abolished C4 fragment deposition. Second, C4 fragment deposition was not observed in the evaluation of C4-free immunoadsorption eluates obtained from highly sensitized dialysis patients. After supplementation with complement, however, eluates induced C4 deposition. Deposition of C4 split products and C1q was temperature-dependent with maximum binding after incubation at 4 degrees C for 60 min. In contrast, maximum C3 fragment deposition was found at 37 degrees C. At this temperature, C3 deposition occurred in an alloantibody and C4-independent fashion, presumably as a result of alternative complement activation. In summary, we describe a novel cell-independent and easy-to-perform PRA test that permits flow cytometry based detection of alloantibody induced classical complement activation. Future studies will have to evaluate its possible relevance as an alternative to CDC-PRA testing in clinical transplantation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12667679     DOI: 10.1016/s0022-1759(03)00012-7

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  11 in total

Review 1.  [Alloantibodies-mediated kidney transplant rejection: a pair of continuing approaches, and with nonetheless many open questions].

Authors:  Georg Böhmig
Journal:  Wien Klin Wochenschr       Date:  2006-07       Impact factor: 1.704

Review 2.  Transplant immuno-diagnostics: crossmatch and antigen detection.

Authors:  Andrew M South; Paul C Grimm
Journal:  Pediatr Nephrol       Date:  2015-07-03       Impact factor: 3.714

3.  Complement activation is not required for obliterative airway disease induced by antibodies to major histocompatibility complex class I: Implications for chronic lung rejection.

Authors:  Masashi Takenaka; Vijay Subramanian; Venkataswarup Tiriveedhi; Donna Phelan; Ramsey Hachem; Elbert Trulock; Andrew E Gelman; G Alexander Patterson; Kiyotaka Hoshinaga; Thalachallour Mohanakumar
Journal:  J Heart Lung Transplant       Date:  2012-09-11       Impact factor: 10.247

4.  Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection.

Authors:  Kazunori Murata; William M Baldwin
Journal:  Transplant Rev (Orlando)       Date:  2009-04-10       Impact factor: 3.943

5.  Bead arrays for antibody and complement profiling reveal joint contribution of antibody isotypes to C3 deposition.

Authors:  Burcu Ayoglu; Eszter Szarka; Krisztina Huber; Anita Orosz; Fruzsina Babos; Anna Magyar; Ferenc Hudecz; Bernadette Rojkovich; Tamás Gáti; György Nagy; Jochen M Schwenk; Gabriella Sármay; József Prechl; Peter Nilsson; Krisztián Papp
Journal:  PLoS One       Date:  2014-05-05       Impact factor: 3.240

Review 6.  Antibody Subclass Repertoire and Graft Outcome Following Solid Organ Transplantation.

Authors:  Nicole M Valenzuela; Michelle J Hickey; Elaine F Reed
Journal:  Front Immunol       Date:  2016-10-24       Impact factor: 7.561

Review 7.  Detection of HLA Antibodies in Organ Transplant Recipients - Triumphs and Challenges of the Solid Phase Bead Assay.

Authors:  Brian D Tait
Journal:  Front Immunol       Date:  2016-12-09       Impact factor: 7.561

Review 8.  From Humoral Theory to Performant Risk Stratification in Kidney Transplantation.

Authors:  C Lefaucheur; D Viglietti; M Mangiola; A Loupy; A Zeevi
Journal:  J Immunol Res       Date:  2017-01-02       Impact factor: 4.818

9.  Effect of the Anti-C1s Humanized Antibody TNT009 and Its Parental Mouse Variant TNT003 on HLA Antibody-Induced Complement Activation-A Preclinical In Vitro Study.

Authors:  M Wahrmann; J Mühlbacher; L Marinova; H Regele; N Huttary; F Eskandary; G Cohen; G F Fischer; G C Parry; J C Gilbert; S Panicker; G A Böhmig
Journal:  Am J Transplant       Date:  2017-03-31       Impact factor: 8.086

10.  C1Q Assay Results in Complement-Dependent Cytotoxicity Crossmatch Negative Renal Transplant Candidates with Donor-Specific Antibodies: High Specificity but Low Sensitivity When Predicting Flow Crossmatch.

Authors:  José M Arreola-Guerra; Natalia Castelán; Adrián de Santiago; Adriana Arvizu; Norma Gonzalez-Tableros; Mayra López; Isaac Salcedo; Mario Vilatobá; Julio Granados; Luis E Morales-Buenrostro; Josefina Alberú
Journal:  J Transplant       Date:  2016-09-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.